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BACKGROUND: Mitochondrial genome sequence analysis is critical to the diagnostic
evaluation of mitochondrial disease. Existing methodologies differ widely in
throughput, complexity, cost efficiency, and sensitivity of heteroplasmy detection.
Affymetrix MitoChip v2.0, which uses a sequencing-by-genotyping technology, allows
potentially accurate and high-throughput sequencing of the entire human
mitochondrial genome to be completed in a cost-effective fashion. However, the
relatively low call rate achieved using existing software tools has limited the wide
adoption of this platform for either clinical or research applications. Here, we report
the design and development of a custom bioinformatics software pipeline that
achieves a much improved call rate and accuracy for the Affymetrix MitoChip v2.0
platform. We used this custom pipeline to analyze MitoChip v2.0 data from 24 DNA
samples representing a broad range of tissue types (18 whole blood, 3 skeletal
muscle, 3 cell lines), mutations (a 5.8 kilobase pair deletion and 6 known
heteroplasmic mutations), and haplogroup origins. All results were compared to
those obtained by at least one other mitochondrial DNA sequence analysis method,
including Sanger sequencing, denaturing HPLC-based heteroduplex analysis, and/or
the Illumina Genome Analyzer II next generation sequencing platform. RESULTS: An
average call rate of 99.75% was achieved across all samples with our custom
pipeline. Comparison of calls for 15 samples characterized previously by Sanger
sequencing revealed a total of 29 discordant calls, which translates to an estimated
0.012% for the base call error rate. We successfully identified 4 known heteroplasmic
mutations and 24 other potential heteroplasmic mutations across 20 samples that
passed quality control. CONCLUSIONS: Affymetrix MitoChip v2.0 analysis using our
optimized MitoChip Filtering Protocol (MFP) bioinformatics pipeline now offers the
high sensitivity and accuracy needed for reliable, high-throughput and cost-efficient
whole mitochondrial genome sequencing. This approach provides a viable alternative
of potential utility for both clinical diagnostic and research applications to traditional
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